Zobrazeno 1 - 10
of 433
pro vyhledávání: '"Sjoerd H. Van Der Burg"'
Autor:
Jim Middelburg, Marjolein Sluijter, Gaby Schaap, Büşra Göynük, Katy Lloyd, Vitalijs Ovcinnikovs, Gijs G. Zom, Renoud J. Marijnissen, Christianne Groeneveldt, Lisa Griffioen, Gerwin G. W. Sandker, Sandra Heskamp, Sjoerd H. van der Burg, Tsolere Arakelian, Ferry Ossendorp, Ramon Arens, Janine Schuurman, Kristel Kemper, Thorbald van Hall
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract CD3 bispecific antibody (CD3 bsAb) therapy is clinically approved for refractory hematological malignancies, but responses in solid tumors have been limited so far. One of the main hurdles in solid tumors is the lack of sufficient T-cell inf
Externí odkaz:
https://doaj.org/article/36795cab2cda485e96053669065dc63a
Autor:
Markus Haake, Beatrice Haack, Tina Schäfer, Patrick N. Harter, Greta Mattavelli, Patrick Eiring, Neha Vashist, Florian Wedekink, Sabrina Genssler, Birgitt Fischer, Julia Dahlhoff, Fatemeh Mokhtari, Anastasia Kuzkina, Marij J. P. Welters, Tamara M. Benz, Lena Sorger, Vincent Thiemann, Giovanni Almanzar, Martina Selle, Klara Thein, Jacob Späth, Maria Cecilia Gonzalez, Carmen Reitinger, Andrea Ipsen-Escobedo, Kilian Wistuba-Hamprecht, Kristin Eichler, Katharina Filipski, Pia S. Zeiner, Rudi Beschorner, Renske Goedemans, Falk Hagen Gogolla, Hubert Hackl, Rogier W. Rooswinkel, Alexander Thiem, Paula Romer Roche, Hemant Joshi, Dirk Pühringer, Achim Wöckel, Joachim E. Diessner, Manfred Rüdiger, Eugen Leo, Phil F. Cheng, Mitchell P. Levesque, Matthias Goebeler, Markus Sauer, Falk Nimmerjahn, Christine Schuberth-Wagner, Stefanie von Felten, Michel Mittelbronn, Matthias Mehling, Andreas Beilhack, Sjoerd H. van der Burg, Angela Riedel, Benjamin Weide, Reinhard Dummer, Jörg Wischhusen
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-19 (2023)
Abstract Immune checkpoint blockade therapy is beneficial and even curative for some cancer patients. However, the majority don’t respond to immune therapy. Across different tumor types, pre-existing T cell infiltrates predict response to checkpoin
Externí odkaz:
https://doaj.org/article/5207814fce1e426b9e431dafa4d554e4
Autor:
Jim Middelburg, Soroush Ghaffari, Tom A.W. Schoufour, Marjolein Sluijter, Gaby Schaap, Büsra Göynük, Benedetta M. Sala, Lejla Al-Tamimi, Ferenc Scheeren, Kees L.M.C. Franken, Jimmy J.L.L. Akkermans, Birol Cabukusta, Simone A. Joosten, Ian Derksen, Jacques Neefjes, Sjoerd H. van der Burg, Adnane Achour, Ruud H.M. Wijdeven, Jon Weidanz, Thorbald van Hall
Publikováno v:
Cell Reports, Vol 42, Iss 12, Pp 113516- (2023)
Summary: The immune checkpoint NKG2A/CD94 is a promising target for cancer immunotherapy, and its ligand major histocompatibility complex E (MHC-E) is frequently upregulated in cancer. NKG2A/CD94-mediated inhibition of lymphocytes depends on the pres
Externí odkaz:
https://doaj.org/article/380d9d0a2508416bb76695633b6aeefe
Autor:
Hella Pasmans, Magdalena A. Berkowska, Annieck M. Diks, Bas de Mooij, Rick J. Groenland, Lia de Rond, M. Alina Nicolaie, Sjoerd H. van der Burg, Jacques J. M. van Dongen, Fiona R. M. van der Klis, Anne-Marie Buisman
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
IntroductionCurrent human papillomavirus (HPV) vaccines consist of virus-like particles (VLPs) which are based on the L1 protein, but they are produced by different expression systems and use different adjuvants. We performed in-depth immunophenotypi
Externí odkaz:
https://doaj.org/article/f4e75bafaffd4056a55afe0cfa67a508
Autor:
Gülçin Gezgin, MD, Marten Visser, MSc, Dina Ruano, PhD, Saskia J. Santegoets, PhD, Noel F.C.C. de Miranda, PhD, Pieter A. van der Velden, PhD, Gregorius P.M. Luyten, MD, PhD, Sjoerd H. van der Burg, PhD, Els M. Verdegaal, PhD, Martine J. Jager, MD, PhD
Publikováno v:
Ophthalmology Science, Vol 2, Iss 2, Pp 100132- (2022)
Purpose: To evaluate whether expanded tumor-infiltrating lymphocytes (TILs) can be obtained from primary uveal melanoma (UM) for potential use as adjuvant treatment in patients at risk of developing metastatic disease. Design: Experimental research s
Externí odkaz:
https://doaj.org/article/3c89ed8a810341619ae83b4be7532151
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Externí odkaz:
https://doaj.org/article/e623f62340564b3bb0969c54e726e83f
Autor:
Jitske van den Bulk, Els M. E. Verdegaal, Dina Ruano, Marieke E. Ijsselsteijn, Marten Visser, Ruud van der Breggen, Thomas Duhen, Manon van der Ploeg, Natasja L. de Vries, Jan Oosting, Koen C. M. J. Peeters, Andrew D. Weinberg, Arantza Farina-Sarasqueta, Sjoerd H. van der Burg, Noel F. C. C. de Miranda
Publikováno v:
Genome Medicine, Vol 11, Iss 1, Pp 1-15 (2019)
Abstract Background The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation does
Externí odkaz:
https://doaj.org/article/1053242894a246058058f9231a19524f
Autor:
Marit J. van Elsas, Johan M. S. van der Schoot, Alexander Bartels, Kas Steuten, Duco van Dalen, Zacharias Wijfjes, Carl G. Figdor, Thorbald van Hall, Sjoerd H. van der Burg, Martijn Verdoes, Ferenc A. Scheeren
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 15, p 8707 (2022)
Regulatory T cells (Tregs) are major drivers behind immunosuppressive mechanisms and present a major hurdle for cancer therapy. Tregs are characterized by a high expression of CD25, which is a potentially valuable target for Treg depletion to allevia
Externí odkaz:
https://doaj.org/article/9b99950f014f4b1bb3ab28ac5b6c67cb
Autor:
Thorbald van Hall, Pascale André, Amir Horowitz, Dan Fu Ruan, Linda Borst, Robert Zerbib, Emilie Narni-Mancinelli, Sjoerd H. van der Burg, Eric Vivier
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Abstract The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now treated with immune system targe
Externí odkaz:
https://doaj.org/article/33a6e9155eae490899e9e33fa89fc794
Autor:
Kim E. Kortekaas, Saskia J. Santegoets, Ziena Abdulrahman, Vanessa J. van Ham, Marij van der Tol, Ilina Ehsan, Helena C. van Doorn, Tjalling Bosse, Mariëtte I. E. van Poelgeest, Sjoerd H. van der Burg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background Vulvar squamous cell carcinoma (VSCC) has been suggested to consist of three subtypes; HPV-positive, HPV-negative mutated TP53 or HPV-negative TP53 wildtype, with different clinical courses. To analyze the immune infiltrate in the
Externí odkaz:
https://doaj.org/article/278594b3dd424428aaf79480406433b9